TY - JOUR
T1 - CEST-Dixon for human breast lesion characterization at 3 T
T2 - A preliminary study
AU - Zhang, Shu
AU - Seiler, Stephen
AU - Wang, Xinzeng
AU - Madhuranthakam, Ananth J.
AU - Keupp, Jochen
AU - Knippa, Emily E.
AU - Lenkinski, Robert E.
AU - Vinogradov, Elena
N1 - Funding Information:
Grant Support: NIH grant R21 EB020245 and the University of Texas Southwestern Medical Center Radiology Research fund. Jochen Keupp is an employee of Philips Research Europe. *Correspondence to: Elena Vinogradov, Ph.D., Department of Radiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390, USA. E-mail: Elena.Vinogradov@UTSouthwestern.edu Received 13 September 2017; revised 24 November 2017; accepted 17 December 2017 DOI 10.1002/mrm.27079 Published online 10 January 2018 in Wiley Online Library (wileyonlinelibrary. com).
Publisher Copyright:
© 2018 International Society for Magnetic Resonance in Medicine
PY - 2018/9
Y1 - 2018/9
N2 - Purpose: Chemical exchange saturation transfer (CEST) MRI for breast lesion characterization is promising. However, artifacts are prone to develop in breast CEST imaging as a result of strong lipid signals. The aims of the study are (i) to develop and validate the CEST-Dixon imaging sequence for simultaneous water-fat separation and B0 mapping; and (ii) use the CEST-Dixon method to characterize suspicious lesions in patients undergoing percutaneous biopsy. Methods: The gradient-echo multi-echo Dixon acquisition is used to create fat-free CEST and B0 maps. The sequence has been validated in phantoms and in vivo. Five healthy volunteers and 10 patients were scanned to compare the CEST contrast in three frequency ranges centered at 1, 2, and 3.5 ppm. The correlation between the CEST contrast and pathology markers (tumor type, estrogen receptor (ER) status, and Ki-67) was also investigated by stratifying the patients into ER-negative invasive ductal carcinoma (IDC) (more aggressive), ER-positive IDC (less aggressive), and benign groups. Results: The CEST-Dixon sequence shows homogenous fat removal in the water-only images. The ER-negative IDC tissues display a trend to higher CEST contrast in all three frequency ranges, whereas the ER-positive IDC, benign, and normal tissues have lower CEST contrast. No significant differences were observed among the ER-positive IDC, benign, and normal tissues. Of the three frequencies ranges, the CEST contrasts at 1 ppm are high in the ER-negative IDC group, have the largest difference among the ER-negative IDC and the other groups, and have the highest correlation with Ki-67. Conclusion: Breast CEST-Dixon imaging shows potential to differentiate more aggressive from less aggressive cancers. Magn Reson Med 80:895–903, 2018.
AB - Purpose: Chemical exchange saturation transfer (CEST) MRI for breast lesion characterization is promising. However, artifacts are prone to develop in breast CEST imaging as a result of strong lipid signals. The aims of the study are (i) to develop and validate the CEST-Dixon imaging sequence for simultaneous water-fat separation and B0 mapping; and (ii) use the CEST-Dixon method to characterize suspicious lesions in patients undergoing percutaneous biopsy. Methods: The gradient-echo multi-echo Dixon acquisition is used to create fat-free CEST and B0 maps. The sequence has been validated in phantoms and in vivo. Five healthy volunteers and 10 patients were scanned to compare the CEST contrast in three frequency ranges centered at 1, 2, and 3.5 ppm. The correlation between the CEST contrast and pathology markers (tumor type, estrogen receptor (ER) status, and Ki-67) was also investigated by stratifying the patients into ER-negative invasive ductal carcinoma (IDC) (more aggressive), ER-positive IDC (less aggressive), and benign groups. Results: The CEST-Dixon sequence shows homogenous fat removal in the water-only images. The ER-negative IDC tissues display a trend to higher CEST contrast in all three frequency ranges, whereas the ER-positive IDC, benign, and normal tissues have lower CEST contrast. No significant differences were observed among the ER-positive IDC, benign, and normal tissues. Of the three frequencies ranges, the CEST contrasts at 1 ppm are high in the ER-negative IDC group, have the largest difference among the ER-negative IDC and the other groups, and have the highest correlation with Ki-67. Conclusion: Breast CEST-Dixon imaging shows potential to differentiate more aggressive from less aggressive cancers. Magn Reson Med 80:895–903, 2018.
KW - CEST
KW - Dixon
KW - Ki-67
KW - breast MRI
KW - breast cancer
KW - estrogen receptor
UR - http://www.scopus.com/inward/record.url?scp=85040508950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040508950&partnerID=8YFLogxK
U2 - 10.1002/mrm.27079
DO - 10.1002/mrm.27079
M3 - Article
C2 - 29322559
AN - SCOPUS:85040508950
VL - 80
SP - 895
EP - 903
JO - Magnetic Resonance in Medicine
JF - Magnetic Resonance in Medicine
SN - 0740-3194
IS - 3
ER -